Milestone Pharmaceuticals Inc. · NASDAQ:MIST
Milestone Pharmaceuticals — World Heart Congress (January 2019)
19 slides from Milestone Pharmaceuticals's conference presentation, January 2019
Slide 1: Prevalence of PSVT in the United States in Patients Under 65 Years of Age
Prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) in the United States in Patients Under 65 Years of Age Naomi C. Sacks, Philip L. Cyr, Stephanie Bariahtaris, Abhishek Sharma, Sarah G. Green, Philippe Douville, Jeremy N. Ruskin
Slide 2: Disclosures
Disclosures This study was funded by Milestone Pharmaceuticals. Dr. Sacks, Mr. Cyr, Mr. Sharma and Ms. Green are employees of Precision Xtract. Dr. Douville is an employee of Milestone Pharmaceuticals. Ms. Bariahtaris received consulting fees from Milestone Pharmaceuticals for this project. Mileston
Slide 3: PSVT is difficult to diagnose and manifests with heart rate increases
PSVT is a condition that is difficult to diagnose and manifests with heart Paroxysmal Supraventricular Tachycardia (PSVT): Episodic, recurring medical condition rate increases that can exceed 200 beats per minute. Paroxysmal Supraventricular Tachycardia (PSVT) Indication • Sporadic, sudden and recur
Slide 4: In the news
In the news.... McAvoy undergoes procedure for ‘abnormal heart rhythm’
Slide 5: PSVT: Prevalence Not Well Characterized in Literature
PSVT: Prevalence Not Well Characterized in Literature MESA Study1 Orejarena et al., J Am Coll Cardiol 1998 Prevalent PSVT cases n=31 from 600 patients’ records as of July STUDY & 1, 1991 POPULATION Incident cases n=33 from 1,163 patients’ records and ECGs July 1991 – June 1993 Marshfield, WI (55,000
Slide 6: PSVT Diagnosis: Challenges for Estimating Prevalence
PSVT Diagnosis: Challenges for Estimating Prevalence Definitive diagnosis of PSVT on a rhythm strip (e.g., ECG, Holter monitor) Prevalence estimates based on chart audits, including a single encounter, may underestimate prevalence, given the episodic nature of PSVT Longitudinal data analyses may pro
Slide 7: Retrospective, Longitudinal Study of PSVT Prevalence Age <65
Retrospective, Longitudinal Study of PSVT Prevalence Age < 65 Employer-Based Claims Data Analysis Estimate PSVT prevalence among patients < age 65 in the U.S. Objective using longitudinal data from a large employer-based claims data set • Elucidate the prevalence of PSVT given the unpredictable onse
Slide 8: Projection Methodology
Projection Methodology Truven Health MarketScan Commercial research database: Data Source demographic, enrollment, medical and prescription drug claims data for 89,800,000 nationally representative, commercially insured individuals over 4 years Patients < age 65 with a PSVT diagnosis (ICD-9: 427.0;
Slide 9: Estimated PSVT Prevalence Using 4-year and Single Year Study Windows
Estimated PSVT Prevalence Among Patients Age < 65 Using 4-year and Single Year Study Windows Estimating prevalence Identify Unique Patients from Longitudinal Data Count unique patients with PSVT Count unique patients with a 1 PSVT diagnosis over the diagnosis code 427.0 or I47.1 PSVT 4-year study pe
Slide 10: Results
Results 10
Slide 11: Results: PSVT Prevalence Estimates for Age <65 from Truven Claims
Results: PSVT Prevalence Estimates for Age < 65 from Truven Claims Projected to US Population Using 4-year and Single Year Study Periods 4-year Observation Period Single Year Observation Period Unique patients with a PSVT Unique PSVT patients only in study diagnosis over the 4-year study period year
Slide 12: Projected PSVT Prevalence Estimates by Age and Sex
Projected PSVT Prevalence Estimates by Age and Sex from Truven Claims Data 2015-2016 (Age < 65) Female Male Total Age < 18 37,959 (3%) 36,648 (3%) 74,606 (6%) Age 18-40 271,015 (22%) 127,250 (10%) 398,265 (32%) Age 41-64 443,825 (36%) 325,969 (26%) 769,794 (62%) Total 751,489 (60%) 491,177 (40%) 1,2
Slide 13: PREEMPT STUDY (Age 18 and older)
PREEMPT STUDY (Age 18 and older) Population-Based Risk and Epidemiology of Paroxysmal Supraventricular Tachycardia Adjudicated medical records, ECGs, other monitoring data to establish positive predictive values (PPVs) for single medical encounters of patients seen at Kaiser Permanente Northern Cali
Slide 14: Maximum PREEMPT PPV Weights Applied to Truven Data Set
Maximum PREEMPT PPV Weights Applied to Truven Data Set for Patient Encounters for PSVT and Other Cardiac Rhythm Disorders PREEMPT Applied PREEMPT PPV weight to Truven Kaiser Permanente Unique Patients (Age <65) NC (Age 18-65) • PREEMPT PPV weights One Year 4-Year were assigned to all 2015- 463,215 9
Slide 15: Summary of Findings
Summary of Findings • Based on coded clinical diagnoses, PSVT affects 1.1 to 1.4 million individuals < age 65 in the U.S. annually • Of these, 444,400 to 734,437 present with a PSVT diagnosis each year • Estimates that rely on a single medical encounter may underestimate PSVT prevalence, including c
Slide 16: Appendix
Appendix 16
Slide 17: Estimated PSVT prevalence in U.S. for all ages, maximum PREEMPT PPV weight
Estimated PSVT prevalence in U.S. for all ages, based on encounter with maximum PREEMPT PPV weight over 4- and 1 year study windows 4 Study Years Study Year only Age < 65 Age < 65 Age 65+ Age 65+ (from Total (from Total (from LDS) (from LDS) Truven) Truven) 2015- 2016 986,504 858,893 1,845,397 463,2
Slide 18: Estimated PSVT Prevalence in the U.S., 4-year and single-year windows
Estimated PSVT Prevalence in the U.S., based on presence of PSVT diagnosis in 4-year and single-year study windows 4 Study Years Study Year only Age < 65 Age < 65 Age 65+ Age 65+ (from Total (from Total (from LDS) (from LDS) Truven) Truven) 2015- 2016 1,246,766 1,655,362 2,902,128 734,437 934,225 1,
Slide 19: PREEMPT Study Results: Prevalence Estimates Projected To U.S. Population
PREEMPT Study Results: PSVT Prevalence Estimates From Kaiser Permanente Northern California Projected To U.S. Population by Age Group Age Group Prevalence estimates per 100,000 2010 Census Data 18-24 23.2 30,767,034 25-44 59.1 82,201,016 45-64 177.5 81,776,168 65+ 479.6 40,480,643 Age Group Point Es
Milestone Pharmaceuticals — World Heart Congress (January 2019) on 6ix